8-K
Acadia Healthcare Company, Inc. (ACHC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 27, 2024 (February 27, 2024)
Acadia Healthcare Company, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 001-35331 | 45-2492228 |
|---|---|---|
| (State or Other Jurisdiction<br><br> <br>of Incorporation) | (Commission File Number) | (IRS Employer<br><br> <br>Identification No.) |
| 6100 Tower Circle, Suite 1000<br><br> <br>Franklin, Tennessee<br><br> <br>(Address of Principal Executive Offices) | 37067<br><br> <br>(Zip Code) | |
| --- | --- |
(615) 861-6000
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | ACHC | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
|---|
On February 27, 2024, Acadia Healthcare Company, Inc. (“Acadia”) issued a press release announcing, among other things, Acadia’s operating and financial results for the fourth quarter and year ended December 31, 2023. The press release is furnished herewith as Exhibit 99 hereto and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
|---|---|
| (d) | Exhibits. |
| --- | --- |
| 99 | Press Release of Acadia Healthcare Company, Inc., dated February 27, 2024. |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| --- | --- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACADIA HEALTHCARE COMPANY, INC. | |||
|---|---|---|---|
| Date: February 27, 2024 | By: | /s/ Heather Dixon | |
| Heather Dixon | |||
| Chief Financial Officer |
ex_631628.htm
Exhibit 99
Contact:
Gretchen Hommrich
Vice President, Investor Relations
(615) 861-6000
ACADIA HEALTHCARE REPORTS FOURTH QUARTER 2023 RESULTS
COMPANY PROVIDES FULL YEAR AND FIRST QUARTER 2024 GUIDANCE
FRANKLIN, Tenn. (February 27, 2024) – Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2023.
Fourth Quarter Highlights
| ● | Revenue totaled $742.8 million, an increase of 10.0% over the fourth quarter of 2022 |
|---|---|
| ● | Same facility revenue increased 10.3% compared with the fourth quarter of 2022, including an increase in revenue per patient day of 7.1% and an increase in patient days of 2.9% |
| --- | --- |
| ● | Net income attributable to Acadia totaled $57.7 million, or $0.63 per diluted share |
| --- | --- |
| ● | Adjusted income attributable to Acadia was $78.3 million, or $0.85 per diluted share, excluding $0.02 of income from the Provider Relief Fund (“PRF”) established under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act |
| --- | --- |
| ● | Adjusted EBITDA was $169.6 million, an increase of 11.9% over the fourth quarter of 2022, excluding income from the PRF in both periods and the impact of a $5.9 million unfavorable adjustment to professional and general liability reserves recorded in the fourth quarter of 2022 |
| --- | --- |
| ● | Continued progress on the execution of the Company’s growth strategy through opening one de novo hospital, adding 98 beds to existing facilities and opening two comprehensive treatment centers (“CTCs”) |
| --- | --- |
| ● | Announced a new joint venture partnership with Ascension Seton, in Austin, Texas, in early January 2024 |
| --- | --- |
Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 9.
Fourth Quarter Results
Chris Hunter, Chief Executive Officer of Acadia, remarked, “Our fourth quarter performance capped off another outstanding year for Acadia. With solid execution, we continued to deliver strong results with impressive annual revenue growth of 12.2% and annual Adjusted EBITDA growth of 13.1%. The momentum in our business reflects the robust demand for behavioral healthcare services. Our outstanding team of employees and clinicians across our facilities have been at the forefront of meeting this demand with safe, high-quality care for behavioral health and substance use issues.
“In addition to delivering our solid financial performance, we made significant improvements to our operations in 2023. Our strategic investments have enabled us to strengthen our core infrastructure and further enhance Acadia’s care delivery. We continue to focus on quality across our operations, leveraging technology and utilizing data to mitigate risk, drive efficiencies and support strong clinical outcomes. As demand for our services continues to accelerate, these investments support our ability to reach more patients and make a positive difference in more communities,” added Hunter.
^1^Excluding income from the PRF
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 2
February 27, 2024
Strategic Investments for Long-Term Growth
During the fourth quarter of 2023 and into the first quarter of 2024, the Company continued to make progress in meeting its strategic growth objectives with the following accomplishments across its five defined growth pathways:
| ● | Facility Expansions – Added 98 beds to existing facilities in the fourth quarter, for a total of 302 new beds added in 2023. The Company expects to add more than 400 beds to existing facilities in 2024. |
|---|---|
| ● | De Novo Facilities – Opened two CTCs, meeting the Company’s goal to open a total of six CTCs in 2023. Acadia opened the renovated 101-bed adult hospital and outpatient facility that are part of the Montrose Behavioral Health Hospital in Chicago, Illinois. During the fourth quarter, the Company also completed construction on an 80-bed inpatient acute care hospital, Coachella Valley Behavioral Health, in Indio, California, which will open later this year. Acadia plans to open up to 14 new CTCs in 2024. |
| --- | --- |
| ● | Joint Ventures – In January 2024, Acadia announced a new joint venture partnership with Ascension Seton, one of the nation’s leading integrated healthcare systems, for a behavioral health hospital in Austin, Texas. This facility, expected to open later in 2024, marks the Company’s second joint venture partnership with Ascension. The Company also expects to open two other previously announced joint venture facilities in 2024, Intermountain Health in Denver, Colorado, and Henry Ford Health in Detroit, Michigan. Acadia has 21 joint venture partnerships for 22 hospitals, with 11 hospitals already in operation and 11 additional hospitals expected to open over the next few years. |
| --- | --- |
| ● | Acquisitions – On February 22, 2024, the Company closed the previously announced acquisition of Turning Point Centers, a 76-bed specialty provider of substance use disorder and primary mental health treatment services that supports the Salt Lake City, Utah, metropolitan market. |
| --- | --- |
| ● | Extend Continuum of Care – Expanded treatment options by adding 13 outpatient programs during the fourth quarter, bringing Acadia’s total to 39 outpatient programs added during 2023. These programs include Partial Hospitalization Programs (PHP), Intensive Outpatient Programs (IOP) or virtual services. |
| --- | --- |
Cash and Liquidity
Maintaining a strong financial position to support growth investments and disciplined capital allocation are top priorities for Acadia. As of December 31, 2023, the Company had $100.1 million in cash and cash equivalents and $516.5 million available under its $600 million revolving credit facility with a net leverage ratio of approximately 1.9x. On January 18, 2024, the Company entered into an Amended Credit Agreement with its lenders to increase its Term Loan A by $350 million. On January 19, 2024, the Company paid $400 million for the settlement of the three cases related to the previously disclosed litigation in New Mexico.
Net leverage ratio is a non-GAAP financial measure. A reconciliation of all non-GAAP financial measures in this press release begins on page 9.
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 3
February 27, 2024
Looking Ahead
Hunter concluded, “The prevalence of behavioral health issues and related deaths is on the rise in our nation. A recent survey by the Centers for Disease Control and Prevention estimated that more than one in five U.S. adults, or nearly 60 million people, live with a mental illness, and over 46 million people have substance use disorders. These illnesses include different conditions that vary in degree of severity and require different modes of treatment. The breadth of our service lines is a key differentiator for Acadia and enhances our ability to support more patients with the appropriate level of high-quality care. With service lines across the continuum of care, strong clinical quality, and a focused operating model, we are well-positioned to continue to lead the behavioral health industry and address these critical needs across the United States. Our 2024 financial guidance reflects our confidence in our ability to drive continued impressive growth and profitability. We are proud of our progress over the past year and look forward to the significant opportunities ahead for Acadia to extend our market reach in 2024.”
Financial Guidance
Acadia today established financial guidance for 2024, as follows:
| 2024 Guidance Range | |
|---|---|
| Revenue ^(1)^ | $3.18 to $3.25 billion |
| Adjusted EBITDA ^(1)^ | $730 to $770 million |
| Adjusted earnings per diluted share ^(1)^ | $3.40 to $3.70 |
| Interest expense | $110 to $120 million |
| Tax rate | 24.5% to 25.5% |
| Depreciation and amortization expense | $150 to $160 million |
| Stock compensation expense | $40 to $45 million |
| Operating cash flows | $525 to $575 million |
| Expansion capital expenditures | $425 to $475 million |
| Maintenance and IT capital expenditures | $90 to $110 million |
| Total bed additions, excluding acquisitions | Approx. 1,200 beds |
| (1) | Includes one-time payments from a state of approximately $10 million (or $0.09 per diluted share) for the year, of which approximately $7 million (or $0.06 per diluted share) was received in the first quarter of 2024 |
| --- | --- |
The Company also established financial guidance for the first quarter of 2024, as follows:
| First Quarter 2024 Guidance Range | |
|---|---|
| Revenue ^(2)^ | $775 to $785 million |
| Adjusted EBITDA ^(2)^ | $170 to $175 million |
| Adjusted earnings per diluted share ^(2)^ | $0.78 to $0.83 |
| (2) | Includes a one-time payment from a state of approximately $7 million (or $0.06 per diluted share) received in the first quarter of 2024 |
| --- | --- |
The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 4
February 27, 2024
Conference Call
Acadia will hold a conference call to discuss its fourth quarter financial results at 7:00 a.m. Central Time/8:00 a.m. Eastern Time on Wednesday, February 28, 2024. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,200 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the U.S. Securities and Exchange Commission.
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 5
February 27, 2024
| Acadia Healthcare Company, Inc. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Condensed Consolidated Statements of Operations | |||||||||||
| (Unaudited) | |||||||||||
| Year Ended December 31, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2022 | 2023 | 2022 | |||||||||
| Revenue | 742,800 | $ | 675,295 | $ | 2,928,738 | $ | 2,610,399 | ||||
| Salaries, wages and benefits (including equity-based compensation expense of 9,149, 7,890, 32,289 and 29,635, respectively) | 400,370 | 365,702 | 1,572,330 | 1,393,434 | |||||||
| Professional fees | 45,545 | 40,295 | 176,013 | 158,013 | |||||||
| Supplies | 26,680 | 25,909 | 105,992 | 100,200 | |||||||
| Rents and leases | 11,672 | 11,682 | 46,552 | 45,462 | |||||||
| Other operating expenses | 98,108 | 93,922 | 388,906 | 349,277 | |||||||
| Income from provider relief fund | (1,977 | ) | (5,245 | ) | (6,419 | ) | (21,451 | ) | |||
| Depreciation and amortization | 35,380 | 30,142 | 132,349 | 117,769 | |||||||
| Interest expense, net | 20,474 | 19,405 | 82,125 | 69,760 | |||||||
| Legal settlements expense | — | — | 394,181 | — | |||||||
| Loss on impairment | 1,096 | — | 9,790 | — | |||||||
| Gain on sale of property | (9,747 | ) | — | (9,747 | ) | — | |||||
| Transaction, legal and other costs | 35,234 | 5,411 | 62,026 | 23,792 | |||||||
| Total expenses | 662,835 | 587,223 | 2,954,098 | 2,236,256 | |||||||
| Income (loss) before income taxes | 79,965 | 88,072 | (25,360 | ) | 374,143 | ||||||
| Provision for (benefit from) income taxes | 20,208 | 24,927 | (9,699 | ) | 94,110 | ||||||
| Net income (loss) | 59,757 | 63,145 | (15,661 | ) | 280,033 | ||||||
| Net income attributable to noncontrolling interests | (2,028 | ) | (2,021 | ) | (6,006 | ) | (6,894 | ) | |||
| Net income (loss) attributable to Acadia Healthcare Company, Inc. | 57,729 | $ | 61,124 | $ | (21,667 | ) | $ | 273,139 | |||
| Earnings (loss) per share attributable to Acadia Healthcare Company, Inc. | |||||||||||
| Basic | 0.63 | $ | 0.68 | $ | (0.24 | ) | $ | 3.05 | |||
| Diluted | 0.63 | $ | 0.67 | $ | (0.24 | ) | $ | 2.98 | |||
| Weighted-average shares outstanding: | |||||||||||
| Basic | 91,238 | 89,897 | 90,949 | 89,680 | |||||||
| Diluted | 91,872 | 91,872 | 90,949 | 91,555 |
All values are in US Dollars.
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 6
February 27, 2024
| Acadia Healthcare Company, Inc. | ||||
|---|---|---|---|---|
| Condensed Consolidated Balance Sheets | ||||
| (Unaudited) | ||||
| December 31, | ||||
| --- | --- | --- | --- | --- |
| 2023 | 2022 | |||
| (In thousands) | ||||
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 100,073 | $ | 97,649 |
| Accounts receivable, net | 361,451 | 322,439 | ||
| Other current assets | 134,476 | 86,037 | ||
| Total current assets | 596,000 | 506,125 | ||
| Property and equipment, net | 2,266,610 | 1,952,045 | ||
| Goodwill | 2,225,962 | 2,222,805 | ||
| Intangible assets, net | 73,278 | 76,041 | ||
| Deferred tax assets | 6,658 | 2,950 | ||
| Operating lease right-of-use assets | 117,780 | 135,238 | ||
| Other assets | 72,553 | 92,697 | ||
| Total assets | $ | 5,358,841 | $ | 4,987,901 |
| LIABILITIES AND EQUITY | ||||
| Current liabilities: | ||||
| Current portion of long-term debt | $ | 29,219 | $ | 21,250 |
| Accounts payable | 156,132 | 104,723 | ||
| Accrued salaries and benefits | 141,901 | 125,298 | ||
| Current portion of operating lease liabilities | 26,268 | 26,463 | ||
| Other accrued liabilities | 532,261 | 110,592 | ||
| Total current liabilities | 885,781 | 388,326 | ||
| Long-term debt | 1,342,548 | 1,364,541 | ||
| Deferred tax liabilities | 1,931 | 92,588 | ||
| Operating lease liabilities | 100,808 | 116,429 | ||
| Other liabilities | 140,113 | 125,033 | ||
| Total liabilities | 2,471,181 | 2,086,917 | ||
| Redeemable noncontrolling interests | 105,686 | 88,257 | ||
| Equity: | ||||
| Common stock | 913 | 899 | ||
| Additional paid-in capital | 2,649,340 | 2,658,440 | ||
| Retained earnings | 131,721 | 153,388 | ||
| Total equity | 2,781,974 | 2,812,727 | ||
| Total liabilities and equity | $ | 5,358,841 | $ | 4,987,901 |
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 7
February 27, 2024
| Acadia Healthcare Company, Inc. | ||||||
|---|---|---|---|---|---|---|
| Condensed Consolidated Statements of Cash Flows | ||||||
| (Unaudited) | ||||||
| Year Ended December 31, | ||||||
| --- | --- | --- | --- | --- | --- | --- |
| 2023 | 2022 | |||||
| (In thousands) | ||||||
| Operating activities: | **** | **** | **** | **** | **** | **** |
| Net (loss) income | $ | (15,661 | ) | $ | 280,033 | |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | **** | **** | **** | **** | **** | **** |
| Depreciation and amortization | 132,349 | 117,769 | ||||
| Amortization of debt issuance costs | 3,322 | 3,261 | ||||
| Equity-based compensation expense | 32,289 | 29,635 | ||||
| Deferred income taxes | (93,984 | ) | 16,545 | |||
| Legal settlements expense | 394,181 | — | ||||
| Loss on impairment | 9,790 | — | ||||
| Gain on sale of property | (9,747 | ) | — | |||
| Other | 3,168 | 2,680 | ||||
| Change in operating assets and liabilities, net of effect of acquisitions: | ||||||
| Accounts receivable, net | (39,012 | ) | (41,978 | ) | ||
| Other current assets | 8,880 | (17,626 | ) | |||
| Other assets | 989 | 2,252 | ||||
| Accounts payable and other accrued liabilities | 17,404 | 5,174 | ||||
| Accrued salaries and benefits | 16,532 | 6,804 | ||||
| Other liabilities | 10,815 | 15,090 | ||||
| Government relief funds | (8,975 | ) | (39,070 | ) | ||
| Net cash provided by operating activities | 462,340 | 380,569 | ||||
| Investing activities: | **** | **** | **** | **** | **** | **** |
| Cash paid for acquisitions, net of cash acquired | (349 | ) | (9,507 | ) | ||
| Cash paid for capital expenditures | (424,133 | ) | (296,149 | ) | ||
| Proceeds from sale of property and equipment | 29,422 | 7,074 | ||||
| Other | (2,159 | ) | (7,248 | ) | ||
| Net cash used in investing activities | (397,219 | ) | (305,830 | ) | ||
| Financing activities: | **** | **** | **** | **** | **** | **** |
| Borrowings on revolving credit facility | 40,000 | — | ||||
| Principal payments on revolving credit facility | (35,000 | ) | (95,000 | ) | ||
| Principal payments on long-term debt | (21,250 | ) | (18,594 | ) | ||
| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises | (44,335 | ) | (6,179 | ) | ||
| Contributions from noncontrolling partners in joint ventures | 2,958 | 15,362 | ||||
| Distributions to noncontrolling partners in joint ventures | (5,107 | ) | (1,004 | ) | ||
| Acquisition of ownership interests from noncontrolling partners | — | (5,540 | ) | |||
| Other | 37 | 52 | ||||
| Net cash used in financing activities | (62,697 | ) | (110,903 | ) | ||
| Net increase (decrease) in cash and cash equivalents | 2,424 | (36,164 | ) | |||
| Cash and cash equivalents at beginning of the period | 97,649 | 133,813 | ||||
| Cash and cash equivalents at end of the period | $ | 100,073 | $ | 97,649 | ||
| $ | - | $ | - | |||
| Effect of acquisitions: | **** | **** | **** | **** | **** | **** |
| Assets acquired, excluding cash | $ | 6,766 | $ | 10,756 | ||
| Liabilities assumed | (128 | ) | (1,249 | ) | ||
| Redeemable noncontrolling interest resulting from an acquisition | (6,289 | ) | — | |||
| Cash paid for acquisitions, net of cash acquired | $ | 349 | $ | 9,507 |
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 8
February 27, 2024
| Acadia Healthcare Company, Inc. | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Statistics | ||||||||||||||||||
| (Unaudited, Revenue in thousands) | ||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||||||||||||
| Same Facility Results ^(1)^ | ||||||||||||||||||
| Revenue | $ | 736,237 | $ | 667,764 | 10.3 | % | $ | 2,897,333 | $ | 2,587,993 | 12.0 | % | ||||||
| Patient Days | 750,660 | 729,233 | 2.9 | % | 3,036,127 | 2,889,465 | 5.1 | % | ||||||||||
| Admissions | 46,481 | 45,788 | 1.5 | % | 194,215 | 185,218 | 4.9 | % | ||||||||||
| Average Length of Stay ^(2)^ | 16.1 | 15.9 | 1.4 | % | 15.6 | 15.6 | 0.2 | % | ||||||||||
| Revenue per Patient Day | $ | 981 | $ | 916 | 7.1 | % | $ | 954 | $ | 896 | 6.5 | % | ||||||
| Adjusted EBITDA margin^(3)^ | 29.1 | % | 27.7 | % | 140 | bps | 29.1 | % | 28.5 | % | 60 | bps | ||||||
| Adjusted EBITDA margin excluding income from provider relief fund | 28.8 | % | 26.9 | % | 190 | bps | 28.9 | % | 27.7 | % | 120 | bps | ||||||
| Facility Results | ||||||||||||||||||
| Revenue | $ | 742,800 | $ | 675,295 | 10.0 | % | $ | 2,928,738 | $ | 2,610,399 | 12.2 | % | ||||||
| Patient Days | 757,345 | 736,695 | 2.8 | % | 3,063,454 | 2,916,500 | 5.0 | % | ||||||||||
| Admissions | 47,295 | 46,375 | 2.0 | % | 197,532 | 186,305 | 6.0 | % | ||||||||||
| Average Length of Stay^(2)^ | 16.0 | 15.9 | 0.8 | % | 15.5 | 15.7 | -0.9 | % | ||||||||||
| Revenue per Patient Day | $ | 981 | $ | 917 | 7.0 | % | $ | 956 | $ | 895 | 6.8 | % | ||||||
| Adjusted EBITDA margin^(3)^ | 27.7 | % | 26.8 | % | 90 | bps | 27.9 | % | 27.9 | % | 0 | bps | ||||||
| Adjusted EBITDA margin excluding income from provider relief fund | 27.5 | % | 26.0 | % | 150 | bps | 27.7 | % | 27.1 | % | 60 | bps | ||||||
| ^(1)^ Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | ||||||||||||||||||
| --- | ||||||||||||||||||
| ^(2)^Average length of stay is defined as patient days divided by admissions. | ||||||||||||||||||
| ^(3)^For each of the three months ended December 31, 2023 and 2022, includes income from provider relief fund of $2.0 million and $5.2 million, respectively. For the year ended December 31, 2023 and 2022, includes income from provider relief fund of $6.4 million and $21.5 million, respectively. |
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 9
February 27, 2024
| Acadia Healthcare Company, Inc. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of Net (Loss) Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2023 | 2022 | 2023 | 2022 | |||||||||
| (in thousands) | ||||||||||||
| Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ | 57,729 | $ | 61,124 | $ | (21,667 | ) | $ | 273,139 | |||
| Net income attributable to noncontrolling interests | 2,028 | 2,021 | 6,006 | 6,894 | ||||||||
| Provision for (benefit from) income taxes | 20,208 | 24,927 | (9,699 | ) | 94,110 | |||||||
| Interest expense, net | 20,474 | 19,405 | 82,125 | 69,760 | ||||||||
| Depreciation and amortization | 35,380 | 30,142 | 132,349 | 117,769 | ||||||||
| EBITDA | 135,819 | 137,619 | 189,114 | 561,672 | ||||||||
| Adjustments: | ||||||||||||
| Equity-based compensation expense (a) | 9,149 | 7,890 | 32,289 | 29,635 | ||||||||
| Transaction, legal and other costs (b) | 35,234 | 5,411 | 62,026 | 23,792 | ||||||||
| Legal settlements expense (c) | — | — | 394,181 | — | ||||||||
| Loss on impairment (d) | 1,096 | — | 9,790 | — | ||||||||
| Gain on sale of property (e) | (9,747 | ) | — | (9,747 | ) | — | ||||||
| Adjusted EBITDA | $ | 171,551 | $ | 150,920 | $ | 677,653 | $ | 615,099 | ||||
| Adjusted EBITDA margin | 23.1 | % | 22.3 | % | 23.1 | % | 23.6 | % | ||||
| Income from provider relief fund | (1,977 | ) | (5,245 | ) | (6,419 | ) | (21,451 | ) | ||||
| Adjusted EBITDA excluding income from provider relief fund | $ | 169,574 | $ | 145,675 | $ | 671,234 | $ | 593,648 | ||||
| Adjusted EBITDA margin excluding income from provider relief fund | 22.8 | % | 21.6 | % | 22.9 | % | 22.7 | % | ||||
| See footnotes on page 11. | ||||||||||||
| --- |
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 10
February 27, 2024
| Acadia Healthcare Company, Inc. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of Net (Loss) Income Attributable to Acadia Healthcare Company, Inc. to | ||||||||||||
| Adjusted Income Attributable to Acadia Healthcare Company, Inc. | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2023 | 2022 | 2023 | 2022 | |||||||||
| (in thousands, except per share amounts) | ||||||||||||
| Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ | 57,729 | $ | 61,124 | $ | (21,667 | ) | $ | 273,139 | |||
| Adjustments to income: | ||||||||||||
| Transaction, legal and other costs (b) | 35,234 | 5,411 | 62,026 | 23,792 | ||||||||
| Legal settlements expense (c) | — | — | 394,181 | — | ||||||||
| Loss on impairment (d) | 1,096 | — | 9,790 | — | ||||||||
| Gain on sale of property (e) | (9,747 | ) | — | (9,747 | ) | — | ||||||
| Provision for (benefit from) income taxes | 20,208 | 24,927 | (9,699 | ) | 94,110 | |||||||
| Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. | 104,520 | 91,462 | 424,884 | 391,041 | ||||||||
| Income tax effect of adjustments to income (f) | 24,750 | 23,405 | 104,697 | 100,067 | ||||||||
| Adjusted income attributable to Acadia Healthcare Company, Inc. | 79,770 | 68,057 | 320,187 | 290,974 | ||||||||
| Income from provider relief fund, net of taxes | (1,441 | ) | (3,822 | ) | (4,678 | ) | (15,631 | ) | ||||
| Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund | $ | 78,329 | $ | 64,235 | $ | 315,509 | $ | 275,343 | ||||
| Weighted-average shares outstanding - diluted (g) | 91,872 | 91,872 | 91,826 | 91,555 | ||||||||
| Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share | $ | 0.87 | $ | 0.74 | $ | 3.49 | $ | 3.18 | ||||
| Income from provider relief fund, net of taxes, per diluted share | (0.02 | ) | (0.04 | ) | (0.05 | ) | (0.17 | ) | ||||
| Adjusted income attributable to Acadia Healthcare Company, Inc., excluding income from provider relief fund, per diluted share | $ | 0.85 | $ | 0.70 | $ | 3.44 | $ | 3.01 | ||||
| See footnotes on page 11. | ||||||||||||
| --- |
- MORE -
ACHC Reports Fourth Quarter 2023 Results
Page 11
February 27, 2024
Acadia Healthcare Company, Inc.
Footnotes
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows:
• EBITDA: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for (benefit from) income taxes, net interest expense and depreciation and amortization.
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, legal settlements expense, loss on impairment and gain on sale of property.
• Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund.
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue.
• Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue.
• Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, legal settlements expense, loss on impairment, gain on sale of property and provision for (benefit from) income taxes.
• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.
• Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund: Adjusted income attributable to Acadia Healthcare Company, Inc. adjusted for income from provider relief fund.
• Net leverage ratio: Long-term debt (excluding $10.4 million of unamortized debt issuance costs, discount and premium) less cash and cash equivalents divided by Adjusted EBITDA for the trailing twelve months.
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses.
(a) Represents the equity-based compensation expense of Acadia.
(b) Represents transaction, legal and other costs incurred by Acadia primarily related to legal, management transition, termination, restructuring, acquisition and other similar costs.
(c) Represents legal settlements expense related to the Desert Hills litigation.
(d) During the three months and year ended December 31, 2023, we recorded non-cash impairment charges totaling $1.1 million and $9.8 million, respectively, related to the closure of certain facilities.
(e) Represents gain on facility property sale.
(f) Represents the income tax effect of adjustments to income based on tax rates of 23.7% and 25.6% for the three months ended December 31, 2023 and 2022, respectively, and 24.6% and 25.6% for the years ended December 31, 2023 and 2022, respectively.
(g) For the year ended December 31, 2023, approximately 0.9 million outstanding shares of restricted stock units and shares of common stock issuable upon exercise of outstanding stock option awards have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for the year ended December 31, 2023 causes such securities to be anti-dilutive.